| Literature DB >> 31244956 |
Do Cong Thang1, Zhimin Wang1, Xiaoling Lu2, Bengang Xing3,1.
Abstract
Nanotechnology-assisted spatiotemporal manipulation of biological events holds great promise in advancing the practice of precision medicine in healthcare systems. The progress in internal and/or external stimuli-responsive nanoplatforms for highly specific cellular regulations and theranostic controls offer potential clinical translations of the revolutionized nanomedicine. To successfully implement this new paradigm, the emerging light-responsive nanoregulators with unparalleled precise cell functions manipulation have gained intensive attention, providing UV-Vis light-triggered photocleavage or photoisomerization studies, as well as near-infrared (NIR) light-mediated deep-tissue applications for stimulating cellular signal cascades and treatment of mortal diseases. This review discusses current developments of light-activatable nanoplatforms for modulations of various cellular events including neuromodulations, stem cell monitoring, immunomanipulation, cancer therapy, and other biological target intervention. In summary, the propagation of light-controlled nanomedicine would place a bright prospect for future medicine.Entities:
Year: 2019 PMID: 31244956 PMCID: PMC6567964 DOI: 10.7150/thno.33888
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Schematic illustration of exosomes for protein loading via optically reversible protein-protein interactions. (Adapted with permission from 75, copyright 2016 Nature Publishing Group)
Figure 8Schematic description of phage display-based breast cancer precision medicine. (A) Selection of patient-specific breast cancer-targeting peptides through in vivo phage display. (B) Coupling of the as-selected peptide with anticancer nanomedicines (AuNRs) to enhance their accumulation inside tumors to achieve highly efficient cancer treatment by photothermal therapy (Adapted with permission from 192, copyright 2017 Nature Publishing Group)
Figure 9Subcellular targeted nanoplatforms for precise tumor phototherapy. (A) Schematic representation of cooperative tumor cell membrane targeting nanosystem (Adapted with permission from 74, copyright 2017 Nature Publishing Group). (B) Schematic illustration of selenium-inserted polymeric nanoparticles (I/D-Se-NPs) with immediate drug release and highly efficient cytoplasmic translocation properties under NIR light exposure for synergistic thermo-chemotherapy (Adapted with permission from 212, copyright 2017 American Chemical Society). (C) Fabrication of PF127/me-IR825 NPs and their applications in mitochondrial imaging, cancer/normal cell differentiation, and mitochondria-targeted PTT (Adapted with permission from 221, copyright 2018 American Chemical Society). (D) the pH-responsive and light triggerable nuclear delivery of 10-hydroxycamptothecine using PPR-NPs (Adapted with permission from 237, copyright 2018 America Chemical Society).
Representative light-responsive nanoparticles for diverse biomedical functions.
| Type of nanomaterials | Size | Wavelength | Functions | Photo-activate mechanisms | Ref. | |
|---|---|---|---|---|---|---|
| Inorganic NPs | AuNR@SiO2 | (L/W):3.4 ± 1.4 | 780 nm | Stimulation of primary auditory neurons | Photothermal | |
| AuNRs@catHDL | Not given | 780 nm | Ca2+ influx by TRPV1 activation in neuronal cells | Photothermal | ||
| AuNRs@NH2-PEG | L, W: 18.5 nm, 71.3 nm | 785 nm | Inhibiting the electrical activity of neuron by activation of TREK-1 thermosensitive potassium channel | Photothermal | ||
| UCNPs | D: 90nm | 980 nm | Deep brain manipulation of neuronal activities. | ChR2 or Arch photoactivation | ||
| UCNP@Ce6-R837 | D: 80nm | 980 nm | Eliminating tumor, long-term immune memory functions. | Photodynamic, photoimmunotherapy | ||
| UCNPs | D: 45 nm | 980 nm | Regulating the function of non-excitable cells, including T lymphocytes, macrophages and dendritic cells | Photoactivation of engineered Opto-CRAC channels | ||
| UCNT@mSiO2- | D: 38±4 nm | 980 nm | Inducing differentiation of hMSCs into hypertrophic chondrocytes, chondrocytes or osteoblasts by regulating Ca2+ intracellular concentration. | Photocleavage induced KGN release | ||
| PEGlated- CuNWs | D: 46 nm; L: 40 µm | 808 nm | Directing cancer ablation and activate effector T cells | Photothermal | ||
| CuS-CpG | D: 85nm | 900 nm | Tumor cell death, tumor antigens release, reduce tumor growth | Photothermal and immunotherapy | ||
| CdTe | 4.5 ± 0.3 nm | 405 nm | Selective DNA cutting between T and A bases of the restriction site GATATC | Photoactivation | ||
| Organic NPs | SPNbc | D: 25 nm | 808 nm | Neuronal control by activation of TRPV1 | Photothermal | |
| PLGA-ICG-R837 | D: 100 nm | 808 nm | Primary tumor ablation, checkpoint-blockades, metastasis inhibition | Photothermal-immunotherapy | ||
| NCP@pyrolipid | D: 55.3±0.2 nm | 670 nm | Tumor cells killing, strong tumor-specific immune response. | Photodynamic-immunotherapy | ||
| GITR-PLGA | D: 142.6 -183.0 nm | 808 nm | Tumor apoptosis/necrosis, Treg cell suppression, immune response | Photothermal-photodynamic-photoimmunotherapy | ||
| MAN-PLGA | D: 78 nm | 808 nm | Eradicating tumors, reprogramming TAMs to an antitumor M1 phenotype, preventing recurrence. | Photodynamic- photoimmunotherapy | ||
| Biomimetic NPs | Fusogenic liposomes (FLs) | D: 126.5 nm | 660 nm | Cooperating with EVs to distribute synthetic receptors-lipid throughout tumor tissues and improve the photosensitive agents' therapeutic responses | Photodynamic | |
| Extracellular vesicles- ChR2 (EVs-ChR2) | D: 100-1000 nm | 480 nm | Transferring engineered ion channel to recipient cells and stimulate its Ca2+ signaling pathways | Photoactivation of ChR2 | ||
| Exosomes | D:186.8 nm (90.8%) | 460 nm | Intracellular delivery of proteins for protein-based therapeutics | Photoactivation of CRY2-CIB1 | ||
Note: D: diameter; L: length; W: width